

November 7, 2022



# Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) --**Immunovant, Inc. (Nasdaq: IMVT)**, a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day, taking place November 14<sup>th</sup>-15<sup>th</sup>, 2022.

## **Guggenheim 4th Annual Immunology and Neurology Day fireside chat details:**

Date: Monday, November 14<sup>th</sup>, 2022

Time: 3:55 pm Eastern Time

Webcast: The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company's website, located at [www.immunovant.com](http://www.immunovant.com).

## **About Immunovant, Inc.**

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. For additional information on the Company, please visit [www.immunovant.com](http://www.immunovant.com).

## **Contact:**

Chau Cheng, PhD, MBA  
Vice President, Investor Relations  
Immunovant, Inc.  
[info@immunovant.com](mailto:info@immunovant.com)

Source: Immunovant Inc.